Frail cancer survivors showed significant gains in strength and immune health after a 10-week personalized resistance training program.
GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01). Phase 1 trial of a KRAS ...
The widespread application of single-cell and spatial omics to models and patient samples has transformed immune cell profiling across physiological conditions. However, knowledge of immune cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results